Literature DB >> 34495388

Operative Approach Does Not Impact Radial Margin Positivity in Distal Rectal Cancer.

George Q Zhang1, Rebecca Sahyoun1, Miloslawa Stem1, Brian D Lo1, Ashwani Rajput1,2,3, Jonathan E Efron1, Chady Atallah1, Bashar Safar4.   

Abstract

BACKGROUND: Robotic surgery is attractive for resection of low rectal cancer due to greater dexterity and visualization, but its benefit is poorly understood. We aimed to determine if operative approach impacts radial margin positivity (RMP) and postoperative outcomes among patients undergoing abdominoperineal resection (APR).
METHODS: This was a retrospective cohort study of patients from the National Surgical Quality Improvement Program who underwent APR for low rectal cancer from 2016 to 2019. Patients were stratified by operative approach: robotic, laparoscopic, and open APR (R-APR, L-APR, and O-APR). Emergent cases were excluded. The primary outcome was RMP. 30-day postoperative outcomes were also evaluated, using logistic regression analysis.
RESULTS: Among 1,807 patients, 452 (25.0%) underwent R-APR, 474 (26.2%) L-APR, and 881 (48.8%) O-APR. No differences regarding RMP (13.5% R-APR vs. 10.8% L-APR vs. 12.3% O-APR, p = 0.44), distal margin positivity, positive nodes, readmission, or operative time were observed between operative approaches. Adjusted analysis confirmed that operative approach did not predict RMP (p > 0.05 for all). Risk factors for RMP included American Society of Anesthesiologists (ASA) classification III (ASA I-II ref; OR 1.46, p = 0.039), pT3-4 stage (T0-2 ref, OR 4.02, p < 0.001), pN2 stage (OR 1.98, p = 0.004), disseminated cancer (OR 1.90, p = 0.002), and lack of preoperative radiation (OR 1.98, p < 0.01).
CONCLUSIONS: No difference in RMP was observed among R-APR, L-APR, and O-APR. Postoperatively, R-APR yielded greater benefit when compared to O-APR, but was comparable to that of L-APR. Minimally invasive surgery may be an appropriate option and worthy consideration for patients with distal rectal cancer requiring APR.
© 2021. Société Internationale de Chirurgie.

Entities:  

Mesh:

Year:  2021        PMID: 34495388     DOI: 10.1007/s00268-021-06278-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  A randomized trial of laparoscopic versus open surgery for rectal cancer.

Authors:  H Jaap Bonjer; Charlotte L Deijen; Gabor A Abis; Miguel A Cuesta; Martijn H G M van der Pas; Elly S M de Lange-de Klerk; Antonio M Lacy; Willem A Bemelman; John Andersson; Eva Angenete; Jacob Rosenberg; Alois Fuerst; Eva Haglind
Journal:  N Engl J Med       Date:  2015-04-02       Impact factor: 91.245

2.  Outcomes in rectal cancer patients undergoing laparoscopic or robotic low anterior resection compared to open: a propensity-matched analysis of the NCDB (2010-2015).

Authors:  Brandon C Chapman; Mark Edgcomb; Ana Gleisner; Jon D Vogel
Journal:  Surg Endosc       Date:  2019-11-14       Impact factor: 4.584

3.  Comparison of short-term and oncologic outcomes of robotic and laparoscopic resection for mid- and distal rectal cancer.

Authors:  Wai Lun Law; Dominic C C Foo
Journal:  Surg Endosc       Date:  2016-10-26       Impact factor: 4.584

4.  Laparoscopic and converted approaches to rectal cancer resection have superior long-term outcomes: a comparative study by operative approach.

Authors:  Deborah S Keller; Zhamak Khorgami; Brian Swendseid; Bradley J Champagne; Harry L Reynolds; Sharon L Stein; Conor P Delaney
Journal:  Surg Endosc       Date:  2014-02-11       Impact factor: 4.584

5.  Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial.

Authors:  Martijn Hgm van der Pas; Eva Haglind; Miguel A Cuesta; Alois Fürst; Antonio M Lacy; Wim Cj Hop; Hendrik Jaap Bonjer
Journal:  Lancet Oncol       Date:  2013-02-06       Impact factor: 41.316

6.  Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial.

Authors:  James Fleshman; Megan Branda; Daniel J Sargent; Anne Marie Boller; Virgilio George; Maher Abbas; Walter R Peters; Dipen Maun; George Chang; Alan Herline; Alessandro Fichera; Matthew Mutch; Steven Wexner; Mark Whiteford; John Marks; Elisa Birnbaum; David Margolin; David Larson; Peter Marcello; Mitchell Posner; Thomas Read; John Monson; Sherry M Wren; Peter W T Pisters; Heidi Nelson
Journal:  JAMA       Date:  2015-10-06       Impact factor: 56.272

7.  Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial.

Authors:  Andrew R L Stevenson; Michael J Solomon; John W Lumley; Peter Hewett; Andrew D Clouston; Val J Gebski; Lucy Davies; Kate Wilson; Wendy Hague; John Simes
Journal:  JAMA       Date:  2015-10-06       Impact factor: 56.272

8.  Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial.

Authors:  Simon S M Ng; Ka Lau Leung; Janet F Y Lee; Raymond Y C Yiu; Jimmy C M Li; Anthony Y B Teoh; Wing Wa Leung
Journal:  Ann Surg Oncol       Date:  2008-04-05       Impact factor: 5.344

9.  Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial.

Authors:  Seung-Yong Jeong; Ji Won Park; Byung Ho Nam; Sohee Kim; Sung-Bum Kang; Seok-Byung Lim; Hyo Seong Choi; Duck-Woo Kim; Hee Jin Chang; Dae Yong Kim; Kyung Hae Jung; Tae-You Kim; Gyeong Hoon Kang; Eui Kyu Chie; Sun Young Kim; Dae Kyung Sohn; Dae-Hyun Kim; Jae-Sung Kim; Hye Seung Lee; Jee Hyun Kim; Jae Hwan Oh
Journal:  Lancet Oncol       Date:  2014-05-15       Impact factor: 41.316

10.  Trends and Outcomes of Surgical Treatment for Colorectal Cancer between 2004 and 2012- an Analysis using National Inpatient Database.

Authors:  Meng-Tse Gabriel Lee; Chong-Chi Chiu; Chia-Chun Wang; Chia-Na Chang; Shih-Hao Lee; Matthew Lee; Tzu-Chun Hsu; Chien-Chang Lee
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.